217 completed, 24 recruiting, 23 unknown, 18 active not recruiting. 328 Phase 3, 26 Phase 2.
Follow Dermatitis: new trials by email Literature Review of Dermatitis trials Research Report on Dermatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age Abrocitinib, Placebo - Atopic Dermatitis | Phase 3 | Not yet recruiting | Pfizer | 90 | 2027-05-01 | 2026-09-16 |
| Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation Dupilumab coformulated with berahyaluronidase alfa, Dupilumab - Dermatitis Atopic | Phase 3 | Not yet recruiting | Sanofi | 150 | 2026-11-30 | 2026-11-05 |
| A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis Lebrikizumab, Placebo - Atopic Dermatitis | Phase 3 | Not yet recruiting | Almirall, S.A. | 230 | 2026-11-01 | 2026-10-14 |
| Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis Roflumilast Cream 0.3%, Vehicle Cream - Atopic Dermatitis, Atopic Dermatitis (AD) | Phase 3 | Recruiting | Arcutis Biotherapeutics, Inc. | 415 | 2026-10-30 | 2026-11-06 |
| Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis Nemolizumab 30 mg, Placebo - Atopic Dermatitis | Phase 3 | Recruiting | Galderma R&D | 240 | 2026-10-08 | 2026-10-16 |
| Oral or Topical Catechins for Radiation Dermatitis Epicatechin, Epigallocatechin Gallate (EGCG), Microcrystalline Cellulose NF (placebo) - Radiation Dermatitis Acute, Radiation Dermatitis | Phase 3 | Enrolling by invitation | CARLOS FRANCISCO SAAVEDRA GARCIA | 162 | 2026-10-01 | 2026-09-11 |
| Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD) 611, Matching placebo - Dermatitis, Atopic | Phase 3 | Recruiting | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 246 | 2026-09-22 | 2026-10-09 |
| A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis Dupilumab Injection, IBI3027 - Atopic Dermatitis | Phase 3 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 520 | 2026-09-15 | 2026-10-15 |
| Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis ADSTEM Inj., Placebo - Atopic Dermatitis | Phase 3 | Recruiting | EHL Bio Co., Ltd. | 286 | 2026-09-15 | 2026-11-13 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profiles of TLL-018 in Patients With Moderate-to-Severe Atopic Dermatitis TLL-018 tablets, Placebo - Atopic Dermatitis (AD) | Phase 2 / Phase 3 | Not yet recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 390 | 2026-08-31 | 2026-08-25 |
| Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis Roflumilast Foam 0.3%, Vehicle foam - Seborrheic Dermatitis | Phase 3 | Not yet recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 309 | 2026-08-24 | 2026-08-21 |
| A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema Tilrekimig, Dupilumab, Placebo for Tilrekimig - Atopic Dermatitis | Phase 3 | Recruiting | Pfizer | 1375 | 2026-08-24 | 2026-11-06 |
| A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema Tilrekimig, Placebo - Atopic Dermatitis | Phase 3 | Recruiting | Pfizer | 375 | 2026-08-17 | 2026-11-12 |
| Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis Crisaborole 2%, Tacrolimus 0.1% - Atopic Dermatitis, Atopic Dermatitis (AD) | Phase 3 | Not yet recruiting | Shalamar Institute of Health Sciences | 66 | 2026-06-01 | 2025-09-09 |
| Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis VC005, VC005 Placebo - Atopic Dermatitis | Phase 3 | Recruiting | Jiangsu vcare pharmaceutical technology co., LTD | 360 | 2026-05-12 | 2026-07-07 |
| A Study to Evaluate the Efficacy and Safety of MG-K10 in Participants Who Have Atopic Dermatitis MG-K10 Humanized Monoclonal Antibody Injection - Atopic Dermatitis, Atopic Eczema | Phase 3 | Not yet recruiting | Shanghai Mabgeek Biotech.Co.Ltd | 498 | 2026-05-01 | 2026-03-18 |
| A Study of Lebrikizumab in Adults With Nummular Eczema Lebrikizumab, Placebo - Nummular Eczema | Phase 3 | Recruiting | Almirall, S.A. | 270 | 2026-04-24 | 2026-08-17 |
| A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis MG-K10 Injection (Humanized Monoclonal Antibody), Placebo for MG-K10 - Dermatitis, Atopic | Phase 3 | Not yet recruiting | Shanghai Mabgeek Biotech.Co.Ltd | 180 | 2026-04-17 | 2026-04-20 |
| Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis Topical application of Periplaneta americana-derived Meilian Fuxin Solution, Topical application of placebo, Radiotherapy - Radiation-induced Dermatitis | Phase 2 / Phase 3 | Recruiting | West China Hospital | 60 | 2026-03-01 | 2026-03-25 |
| A Phase III Study of GS101 Injection to Dupixent® GS101 injection, DUPIXENT® - Atopic Dermatitis (AD) | Phase 3 | Recruiting | Jiangsu Genscend Biopharmaceutical Co., Ltd | 572 | 2026-01-29 | 2026-10-15 |
Showing 20 of 328. Sign in to see all of them.
Dermatitis, Atopic (236) · Eczema (85) · Skin Diseases (27) · Radiodermatitis (18) · Pruritus (16) · Breast Neoplasms (15) · Hypersensitivity (12) · Hand-Foot Syndrome (11) · Skin Diseases, Eczematous (10) · Skin Diseases, Genetic (9) · Immune System Diseases (8) · Neurodermatitis (8) · Psoriasis (8) · Dermatitis, Seborrheic (7)
Skin and Connective Tissue Diseases (328) · Skin Diseases (301) · Skin Diseases, Eczematous (266) · Immune System Diseases (241) · Hypersensitivity (237) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (236) · Hypersensitivity, Immediate (233) · Genetic Diseases, Inborn (230) · Skin Diseases, Genetic (227) · Pathological Conditions, Signs and Symptoms (31) · Signs and Symptoms (23) · Wounds and Injuries (20) · Neoplasms (19) · Neoplasms by Site (19)
dupilumab (28) · lebrikizumab (18) · Adrenal Cortex Hormones (17) · pimecrolimus (12) · upadacitinib (12) · abrocitinib (11) · tralokinumab (10) · difamilast (9) · Tacrolimus (8) · baricitinib (8) · secukinumab (7) · nemolizumab (5) · Calcineurin Inhibitors (4) · entacapone (4) · Cyclosporine (3)
Eli Lilly and Company (21) · Pfizer (19) · Sanofi (14) · AbbVie (12) · LEO Pharma (12) · Novartis Pharmaceuticals (11) · Incyte Corporation (10) · Regeneron Pharmaceuticals (10) · Amgen (8) · Almirall, S.A. (6) · Astellas Pharma Inc (6) · Organon and Co (6) · Otsuka Pharmaceutical Co., Ltd. (6) · Fougera Pharmaceuticals Inc. (5) · Galderma R&D (5)
United States (137) · Canada (86) · Germany (86) · Poland (74) · China (71) · Spain (67) · Japan (61) · France (60) · United Kingdom (55) · Italy (54) · South Korea (47) · Australia (45) · Czechia (40) · Hungary (40) · Taiwan (36)
Angela C Kaplan (4) · Diana Villalobos (3) · Lin Ma (3)
PMID 39588375, PMID 33826132, PMID 42162528, PMID 40993471, PMID 34406619, PMID 36255569, PMID 36723913, PMID 38896380, PMID 40028832, PMID 31066001, PMID 33165005, PMID 33453450, PMID 34142350, PMID 35636689, PMID 36749121, PMID 36808602, PMID 39104653, PMID 40555305, PMID 41118053, PMID 31407311, PMID 31424712, PMID 34037993, PMID 34275122, PMID 34688290, PMID 34726270, PMID 34743361, PMID 34897582, PMID 35305260, PMID 35342978, PMID 35714786, PMID 36152216, PMID 36754548, PMID 37043227, PMID 37247226, PMID 38777187, PMID 39110139, PMID 39441580, PMID 40085349, PMID 40383273, PMID 40457140, PMID 40600584, PMID 40875187, PMID 40900410, PMID 41206702, PMID 42365219, PMID 42530735, PMID 27417017, PMID 27690741, PMID 28503712, PMID 30345457
2023 (13), 2018 (12), 2019 (11), 2017 (10), 2016 (4), 2025 (4), 2008 (2), 2015 (2), 2009 (1), 2014 (1), U10CA037420 (1)